Comparison of Coagulation Parameters between Severe and Non-severe COVID-19 Patients Treated in a Tertiary Hospital in Indonesia

Authors

  • Pandji Irani Fianza Department Internal Medicine Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital Bandung
  • Delita Prihatni Department of Clinical Pathology Faculty of Medicine Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital Bandung
  • Dasep Bambang Purnama Department Internal Medicine Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital Bandung

DOI:

https://doi.org/10.15850/ijihs.v11n2.2967

Keywords:

Coagulopathy disorders, COVID-19, severe acute respiratory syndrome, non-severe acute respiratory syndrome

Abstract

Objective: To determine the differences in coagulation features in patients with severe versus non-severe COVID-19.

Method: During the period of the study from July 2020 to June 2021, 371 COVID-19 patients were treated at Dr. Hasan Sadikin Hospital. These patients were divided into two groups based on the WHO critera into severe COVID-19 with clinical signs such as severe acute respiratory syndrome to respiratory failure and non-severe cases with no respiratory symptoms. Data analyzed were Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), International Normalized Ratio (INR), fibrinogen, D-dimer, and platelet count.

Results: Median INR was significantly higher in patients with severe cases than in non-severe cases (1.04 vs. 0.94, p<0.001), which was also true for median PT (12.3 vs. 12.0 sec, p=0.030) and median fibrinogen (522 vs. 428.5 mg/dl, p=0.004). Similarly, the median D-dimer was significantly higher in severe patients (1.91 vs. 0.75 mg/dl, p<0.001). Median aPTT and platelet count were in normal limits for both severe and non-severe COVID-19 patients (28.6 vs. 29.15 sec, p>0.652 and 246 vs. 242 x103/mm3, p>0.924, respectively).

Conclusions: The INR, PT, fibrinogen, and D-dimer can be considered as features that can be used to predict the severity of the disease and to choose the proper treatment for COVID-19 patients.

References

  1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. 2021. Available from: https://covid19.go.int/.
  2. Badan Nasional Penanggulangan Bencana. Tingkat Kematian (CFR) Covid-19 Indonesia. 2021. Available from: https://bnpb.go.id/.
  3. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7. doi:10.1002/path.1570
  4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi:10.1016/j.jaut.2020. 102433
  5. Soeroto AY SP, Pranggono EH, Kulsum ID, Suryadinata H,. Pedoman diagnostik dan pengobatan COVID-19. Indones J Chest Crtitical Emerg Med. 2020;1:7.
  6. Mackman N, Antoniak S, Wolberg AS, Kasthuri R, Key NS. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler Thromb Vasc Biol. 2020;40(9):2033–44. doi:10.1161/ATVBAHA.120.314514
  7. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. doi:10.1016/j.thromres.2020.04.024
  8. Dahler C, Rechner GA, Mitsios JV. Pathophysiology of COVID-19-associated coagulopathy and its impact on laboratory measures of coagulation. J Pathogen. 2021:30.
  9. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54–67. doi:10.1007/s11239-020-02134-3
  10. Lazzaroni MG, Piantoni S, Masneri S, et al. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2021;46:100745. doi:10.1016/j.blre.2020.100745
  11. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13. doi:10.1016/S0140-6736(20)30211-7
  12. Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021;76(4):412–20. doi:10.1136/thoraxjnl-2020-216243
  13. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. doi:10.1016/S2352-3026(20)30145-9
  14. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9): 2103–9. doi:10.1111/jth.14975
  15. Kim ES, Chin BS, Kang CK, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19. J Korean Med Sci. 2020;35(13):e142. doi:10.3346/jkms.2020.35.e142
  16. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145–8. doi:10.1016/j.cca.2020.03.022

Downloads

Published

2023-09-30

Issue

Vol. 11 No. 2 (2023)

Section

Articles

License

Authors retain copyright and grant International Journal of Integrated Health Sciences right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to freely share and remix the work with an acknowledgement of the work's authorship and initial publication in International Journal of Integrated Health Sciences.